Patricia T Illing

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4248752/publications.pdf

Version: 2024-02-01

39 papers	2,186 citations	331670 21 h-index	345221 36 g-index
40 all docs	40 docs citations	40 times ranked	3285 citing authors

#	Article	IF	Citations
1	Editorial: The Immunology of Adverse Drug Reactions. Frontiers in Immunology, 2022, 13, 863414.	4.8	0
2	HLA-A*11:01-restricted CD8+ T cell immunity against influenza A and influenza B viruses in Indigenous and non-Indigenous people. PLoS Pathogens, 2022, 18, e1010337.	4.7	11
3	T Cell Epitope Discovery in the Context of Distinct and Unique Indigenous HLA Profiles. Frontiers in Immunology, 2022, 13, .	4.8	4
4	New insights and approaches for analyses of immunopeptidomes. Current Opinion in Immunology, 2022, 77, 102216.	5.5	3
5	The complexity of T cellâ€“mediated penicillin hypersensitivity reactions. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 150-167.	5.7	11
6	Anthem: a user customised tool for fast and accurate prediction of binding between peptides and HLA class I molecules. Briefings in Bioinformatics, 2021, 22, .	6.5	37
7	Carbamazepine Induces Focused T Cell Responses in Resolved Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Cases But Does Not Perturb the Immunopeptidome for T Cell Recognition. Frontiers in Immunology, 2021, 12, 653710.	4.8	14
8	Resourcing, annotating, and analysing synthetic peptides of SARSâ€CoVâ€2 for immunopeptidomics and other immunological studies. Proteomics, 2021, 21, e2100036.	2.2	7
9	CD8+ T cell landscape in Indigenous and non-Indigenous people restricted by influenza mortality-associated HLA-A*24:02 allomorph. Nature Communications, 2021, 12, 2931.	12.8	20
10	Kinetics of Abacavir-Induced Remodelling of the Major Histocompatibility Complex Class I Peptide Repertoire. Frontiers in Immunology, 2021, 12, 672737.	4.8	8
11	ggVolcanoR: A Shiny app for customizable visualization of differential expression datasets. Computational and Structural Biotechnology Journal, 2021, 19, 5735-5740.	4.1	19
12	A natural product compound inhibits coronaviral replication inÂvitro by binding to the conserved Nsp9 SARS-CoV-2 protein. Journal of Biological Chemistry, 2021, 297, 101362.	3.4	35
13	Modification of the cyclopropyl moiety of abacavir provides insight into the structure activity relationship between HLAâ€B*57:01 binding and Tâ€cell activation. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 636-647.	5.7	19
14	Identification of Flucloxacillin-Haptenated HLA-B*57:01 Ligands: Evidence of Antigen Processing and Presentation. Toxicological Sciences, 2020, 177, 454-465.	3.1	21
15	Thermostability profiling of MHC-bound peptides: a new dimension in immunopeptidomics and aid for immunotherapy design. Nature Communications, 2020, 11, 6305.	12.8	14
16	Immunopeptidomic Analysis Reveals That Deamidated HLA-bound Peptides Arise Predominantly from Deglycosylated Precursors. Molecular and Cellular Proteomics, 2020, 19, 1236-1247.	3.8	25
17	The molecular basis of how buried human leukocyte antigen polymorphism modulates natural killer cell function. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 11636-11647.	7.1	16
18	Response to Comment on â€œA subset of HLA-I peptides are not genomically templated: Evidence for cis- and trans-spliced peptide ligandsâ€. Science Immunology, 2019, 4, .	11.9	25

#	Article	IF	Citations
19	Downregulation of MHC Class I Expression by Influenza A and B Viruses. Frontiers in Immunology, 2019, 10, 1158.	4.8	65
20	HLAâ€associated antiepileptic drugâ€induced cutaneous adverse reactions. Hla, 2019, 93, 417-435.	0.6	52
21	Human CD8+ T cell cross-reactivity across influenza A, B and C viruses. Nature Immunology, 2019, 20, 613-625.	14.5	180
22	Identification of Native and Posttranslationally Modified HLAâ€B*57:01â€Restricted HIV Envelope Derived Epitopes Using Immunoproteomics. Proteomics, 2018, 18, e1700253.	2.2	23
23	HLA-B57 micropolymorphism defines the sequence and conformational breadth of the immunopeptidome. Nature Communications, 2018, 9, 4693.	12.8	31
24	A subset of HLA-I peptides are not genomically templated: Evidence for cis- and trans-spliced peptide ligands. Science Immunology, 2018, 3, .	11.9	142
25	Employing proteomics in the study of antigen presentation: an update. Expert Review of Proteomics, 2018, 15, 637-645.	3.0	23
26	MHC-I peptides get out of the groove and enable a novel mechanism of HIV-1 escape. Nature Structural and Molecular Biology, 2017, 24, 387-394.	8.2	83
27	The molecular basis for peptide repertoire selection in the human leukocyte antigen (HLA) C*06:02 molecule. Journal of Biological Chemistry, 2017, 292, 17203-17215.	3.4	34
28	The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions. Immunogenetics, 2017, 69, 617-630.	2.4	63
29	Allotype specific interactions of drugs and HLA molecules in hypersensitivity reactions. Current Opinion in Immunology, 2016, 42, 31-40.	5.5	47
30	HLA and Drug Hypersensitivity. , 2016, , 310-317.		0
31	A comprehensive analysis of peptides presented by HLAâ€A1. Tissue Antigens, 2015, 85, 492-496.	1.0	27
32	The Cellular Redox Environment Alters Antigen Presentation. Journal of Biological Chemistry, 2014, 289, 27979-27991.	3.4	52
33	Using mass spectrometry to monitor drug induced changes in antigen presentation by the human leukocyte antigen. Clinical and Translational Allergy, 2014, 4, P43.	3.2	0
34	Human leukocyte antigen-associated drug hypersensitivity. Current Opinion in Immunology, 2013, 25, 81-89.	5.5	76
35	Structural insight into MR1-mediated recognition of the mucosal associated invariant T cell receptor. Journal of Experimental Medicine, 2012, 209, 761-774.	8.5	159
36	Constitutive and Inflammatory Immunopeptidome of Pancreatic Î²-Cells. Diabetes, 2012, 61, 3018-3025.	0.6	67

#	Article	IF	Citations
37	Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature, 2012, 486, 554-558.	27.8	612
38	Drug Hypersensitivity and Human Leukocyte Antigens of the Major Histocompatibility Complex. Annual Review of Pharmacology and Toxicology, 2012, 52, 401-431.	9.4	146
39	Personalized medicine for HLA-associated drug-hypersensitivity reactions. Personalized Medicine, 2010, 7, 495-516.	1.5	15